Capecitabine and vinorelbine as an all-oral chemotherapy in HER2-negative locally advanced and metastatic breast cancer

Breast Care

Volumn 5, Issue 3, 2010, Pages 158-162

  Gampenrieder, Simon P ^a   Bartsch, Rupert ^a   Matzneller, Peter ^a   Pluschnig, Ursula ^a   Dubsky, Peter ^a   Gnant, Michael X ^a   Zielinski, Christoph C ^a   Steger, Guenther G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Breast cancer, advanced; Capecitabine; Combination therapy; Vinorelbine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAVELBINE; NAVELBINE ORAL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; POLYNEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 77954500272     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000314214     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Findlay M, von Minckwitz G, Wardley A: Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol 2008;19:212-222.
3. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B: Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92:1759-1768.
4. Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Conejo E, Ackland S, Eisenberg P, Melnychuk D, Pienkowski T, Burger HU, Laws S, Osterwalder B: Randomised, phase II trial comparing oral capecitabine (xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86: 1367-1372.
5. O'Shaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU, Laws S: Randomized, openlabel, phase II trial of oral capecitabine (xeloda) vs. A reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as firstline therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12:1247-1254.
6. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT, et al.: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11:1245-1252.
7. Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, Hohneker J: Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995;13:2722-2730.
8. Terenziani M, Demicheli R, Brambilla C, Ferrari L, Moliterni A, Zambetti M, Caraceni A, Martini C, Bonadonna G: Vinorelbine: an active, non crossresistant drug in advanced breast cancer. Results from a phase II study. Breast Cancer Res Treat 1996;39:285-291.
9. Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, Locker GJ, Mader R, Zielinski CC, Steger GG: Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial. Cancer Chemother Pharmacol 2006;57:554-558.
10. Baweja M, Suman VJ, Fitch TR, Mailliard JA, Bernath A, Rowland KM, Alberts SR, Kaur JS, Perez EA: Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or = 65 years of age: an NCCTG study. Ann Oncol 2006;17:623-629.
11. Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, Imadalou K, Trillet-Lenoir V: Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 2003;21:35-40.
12. Winer EP, Chu L, Spicer DV: Oral vinorelbine (navelbine) in the treatment of advanced breast cancer. Semin Oncol 1995;22:72-78; discussion 78-79.
13. Sawada N, Fujimoto-Ouchi K, Ishikawa T: Antitumor activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proc Am Assoc Cancer Res 2002;21:(abstr 5388).
14. Ghosn M, Kattan J, Farhat F, Younes F, Gasmi J: Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients. Anticancer Res 2006;26:2451-2456.
15. Welt A, von Minckwitz G, Oberhoff C, Borquez D, Schleucher R, Loibl S, Harstrick A, Kaufmann M, Seeber S, Vanhoefer U: Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 2005;16:64-69.
16. Estevez LG, Batista N, Sanchez-Rovira P, Velasco A, Provencio M, Leon A, Domine M, Cruz J, Rodriguez M: A phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer 2008;8:149-154. (Pubitemid 351655929)
17. Kellokumpu-Lehtinen PL, Sunela K, Lehtinen I, Joensuu H, Sjostrom-Mattson J: A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes. Clin Breast Cancer 2006;7:401-405.
18. Nole F, Catania C, Sanna G, Imadalou K, Munzone E, Adamoli L, Longerey B, Blanchot G, Goldhirsch A: Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 2006;17:322-329.
19. Delcambre C, Veyret C, Levy C, Switsers O: A phase I/II study of capecitabine (x) combined with oral vinorelbine (n) as first- or second-line chemotherapy in patients (pts) with locally advanced breast cancer (MBC). Breast Cancer Res Treat 2005;24:67(abstr 1081).
20. Lorusso V, Spada M, Giampaglia M, Misino A, Calabrese R, Latorre A, Monticelli G, Guida M, Sambiasi D, Colucci G: Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (gruppo oncologico dell'italia meridionale). Ann Oncol 2006;17(suppl 7):vii15-17.
21. Tubiana-Mathieu N, Bougnoux P, Becquart D, Chan A, Majois F: Phase II study of an alloral combination of oral vinorelbine (nvbo) and capecitabine (x) in HER2-negative metastatic breast cancer (MBC): first results of an international phase II trial. Breast Cancer Res Treat 2006; 100:280(abstr 6072).
22. Finek J, Holubec L, Jr., Svoboda T, Sefrhansova L, Pavlikova I, Votavova M, Sediva M, Filip S, Kozevnikova R, Kormunda S: A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. Anticancer Res 2009;29:667-670.
23. Nole F, Crivellari D, Mattioli R, Pinotti G, Foa P, Verri E, Fougeray R, Brandely M, Goldhirsch A: Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 2009;64:673-680.
24. Oshaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU, Laws S: Randomized, openlabel, phase II trial of oral capecitabine (xeloda) vs. A reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as firstline therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12:1247-1254.
25. Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB, Ambrosini G: Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 1994;12:2094-2101.
26. Ghosn M, Kattan J, Farhat F, Younes F, Nasr F, Moukadem W, Gasmi J, Chahine G: Sequential vinorelbine-capecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial. Cancer Chemother Pharmacol 2008; 62:11-18.
27. Mano M: Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy. Cancer Treat Rev 2006;32:106-118.